Business · 09/12/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for BEPREVE Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of BEPREVE, a human drug product, as required by law. This decision was prompted by a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →